Skip to main content

Febit Biotech, Epicentre Biotechnologies, NoAb BioDiscoveries

Febit Biotech this week launched its Geniom RT Analyzer system for sample hybridization, automated processing, and analysis.
The system is designed to be used in combination with Geniom biochips that have been synthesized on Febit’s Geniom One instrument in the customer’s lab, or purchased as Ready-to-Go Biochips directly from Febit.
The content of Geniom Ready-to-Go Biochips can be chosen from a portfolio of digital microarrays provided by Febit, or from public databases, amended or supplemented by additional genomic information specific to each customer, the company said.

Epicentre Biotechnologies last week launched its Moloney Murine Leukemia Virus Reverse Transcriptase 1st-Strand cDNA Synthesis Kit for generating full-length, first-strand cDNA from total RNA or purified polyadenylated RNA-enriched samples.
The kit features Epicentre's high activity formulation MMLV Reverse Transcriptase and 10X Reaction Buffer, which the firm claims enables the production of full-length cDNA longer than 15 kb from mRNA templates using an oligo primer.

NoAb BioDiscoveries last week launched DTEx, a microarray-based technology for profiling the effects of drugs on the expression of key proteins involved in drug disposition.
Specifically, Toronto-based NoAb is offering DTEx-ABC, a service for gene expression profiling of the human efflux drug transporters; DTEx-ADME for gene expression profiling of key human efflux and uptake drug transporters, Phase I and II metabolic enzymes, and nuclear factors; and DTEx-Custom for gene expression profiling of human genes selected by the client from the NoAb BioDiscoveries gene palette.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.